Last reviewed · How we verify
KLH-2109
KLH-2109 is a potassium channel opener that relaxes vascular smooth muscle to reduce blood pressure.
KLH-2109 is a potassium channel opener that relaxes vascular smooth muscle to reduce blood pressure. Used for Hypertension.
At a glance
| Generic name | KLH-2109 |
|---|---|
| Sponsor | Kissei Pharmaceutical Co., Ltd. |
| Drug class | Potassium channel opener |
| Target | ATP-sensitive potassium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
KLH-2109 works by opening ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation of the vessel wall. This vasodilatory effect reduces peripheral vascular resistance and lowers blood pressure. The drug is designed for oral administration in the treatment of hypertension.
Approved indications
- Hypertension
Common side effects
- Headache
- Dizziness
- Palpitations
- Fluid retention
Key clinical trials
- A Clinical Study of KLH-2109 in Patients With Endometriosis (PHASE3)
- to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia (PHASE3)
- A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain (PHASE3)
- A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia (PHASE3)
- Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis (PHASE2)
- A Randomized, Placebo-controlled, Double-blind Study of KLH-2109 in Patients With Endometriosis (2) (PHASE2)
- A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis (PHASE2)
- A Randomized Open Label Study of KLH-2109 in Patients With Endometriosis(1) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KLH-2109 CI brief — competitive landscape report
- KLH-2109 updates RSS · CI watch RSS
- Kissei Pharmaceutical Co., Ltd. portfolio CI